Literature DB >> 22067329

KBA62 and PNL2: 2 new melanoma markers-immunohistochemical analysis of 1563 tumors including metastatic, desmoplastic, and mucosal melanomas and their mimics.

Phyu Phyu Aung1, Maarit Sarlomo-Rikala, Jerzy Lasota, Jin-Ping Lai, Zeng-Feng Wang, Markku Miettinen.   

Abstract

Identification of metastatic melanoma can be difficult because of its considerable morphologic variation and mimicry of a wide variety of other tumors. The more melanoma-specific melanoma markers, MelanA/MART-1, HMB45, and tyrosinase, used in addition to S100 protein, all have limitations in sensitivity and specificity. In this study, we evaluated 2 new melanoma markers, monoclonal antibodies KBA62 and PNL2 to yet unidentified antigens, using a large panel of metastatic melanomas (n=214), desmoplastic melanomas (n=34), gastrointestinal mucosal melanomas (n=54), benign nevi (n=27), clear cell sarcomas (n=16), and nonmelanocytic tumors (n=1218). Immunoreactivity for KBA62 and PNL2 was found in all pigmented nevi and in 86% and 90% of metastatic melanomas, respectively. Mucosal melanomas showed a similar rate of PNL2 immunoreactivity but somewhat less frequent KBA62 positivity (72%). In addition, KBA62 was found to be a sensitive diagnostic marker for desmoplastic melanoma (28 of 34; 82%), whereas PNL2 was only rarely positive (2 of 34; 6%). KBA62-positive normal tissues included pericytes, vascular and parenchymal smooth muscles, and basal cells of complex epithelia, including myoepithelia, whereas PNL2 labeled only melanocytes and neutrophils. Among nonmelanocytic tumors, those that were KBA62 positive were nodular fasciitis, leiomyoma and leiomyosarcoma, gastrointestinal stromal tumors, benign and malignant nerve sheath tumors, synovial sarcoma, and subsets of various carcinomas, especially those with squamous cell/stratified epithelial differentiation. PNL2 positivity in nonmelanocytic tumors was more restricted but occurred consistently in angiomyolipoma and other perivascular epitheloid cell tumor and in chronic myeloid leukemia tissue infiltrates. KBA62 may assist in the identification of desmoplastic melanomas, but its widespread occurrence in nonmelanomas limits utility. PNL2 is highly specific for melanomas but lacks reactivity with desmoplastic melanomas. It is also an excellent supplementary marker for perivascular epitheloid cell tumor at various sites.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22067329      PMCID: PMC3261309          DOI: 10.1097/PAS.0b013e31823651cb

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  9 in total

1.  Uterine perivascular epitheloid cell tumor (PEComa) with CD117 and PNL2 positivity and entrapped endometriotic glands, mimicking sex-cordlike differentiation.

Authors:  Lars-Christian Horn; Jens Einenkel
Journal:  Ann Diagn Pathol       Date:  2011-03-10       Impact factor: 2.090

2.  Immunohistochemical analysis of novel monoclonal antibody PNL2 and comparison with other melanocyte differentiation markers.

Authors:  Klaus J Busam; Derya Kucukgöl; Eiichi Sato; Denise Frosina; Julie Teruya-Feldstein; Achim A Jungbluth
Journal:  Am J Surg Pathol       Date:  2005-03       Impact factor: 6.394

3.  Immunohistochemical evaluation of necrotic malignant melanomas.

Authors:  Daisuke Nonaka; Jordan Laser; Rachel Tucker; Jonathan Melamed
Journal:  Am J Clin Pathol       Date:  2007-05       Impact factor: 2.493

4.  Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers.

Authors:  M Miettinen; M Fernandez; K Franssila; Z Gatalica; J Lasota; M Sarlomo-Rikala
Journal:  Am J Surg Pathol       Date:  2001-02       Impact factor: 6.394

5.  Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections.

Authors:  O Kaufmann; S Koch; J Burghardt; H Audring; M Dietel
Journal:  Mod Pathol       Date:  1998-08       Impact factor: 7.842

6.  PNL2, a new monoclonal antibody directed against a fixative-resistant melanocyte antigen.

Authors:  Philippe Rochaix; Magali Lacroix-Triki; Laurence Lamant; Carole Pichereaux; Severine Valmary; Elena Puente; Talal Al Saati; Bernard Monsarrat; Christiane Susini; Louis Buscail; Georges Delsol; Jean-Jacques Voigt
Journal:  Mod Pathol       Date:  2003-05       Impact factor: 7.842

7.  KBA.62: a useful marker for primary and metastatic melanomas.

Authors:  Cécile Pagès; Philippe Rochaix; Talal al Saati; Séverine Valmary-Degano; Serge Boulinguez; François Launay; Paul Carle; Frédéric Lauwers; Pierre Payoux; Sophie Le Guellec; Pierre Brousset; Laurence Lamant
Journal:  Hum Pathol       Date:  2008-05-20       Impact factor: 3.466

8.  PNL2 melanocytic marker in immunohistochemical evaluation of primary mucosal melanoma of the head and neck.

Authors:  Luc G Morris; Yong Hannah Wen; Daisuke Nonaka; Mark D DeLacure; David I Kutler; Youming Huan; Beverly Y Wang
Journal:  Head Neck       Date:  2008-06       Impact factor: 3.147

9.  Production and characterisation of an antimelanoma monoclonal antibody KBA.62 using a new melanoma cell line reactive on paraffin wax embedded sections.

Authors:  E Cohen-Knafo; T al Saati; J Aziza; E Ralfkiaer; J Selves; B Gorguet; G Delsol
Journal:  J Clin Pathol       Date:  1995-09       Impact factor: 3.411

  9 in total
  5 in total

1.  Atypical fibroxanthoma-a diagnosis of exclusion!

Authors:  Georgi Tchernev; Michael Tronnier; Julian Ananiev; Teodora Taneva; James W Patterson; Maya Gulubova; John P Trafeli; Antonina Gegova; Mason Harrell; Claudio Guarneri; Uwe Wollina; José Carlos Cardoso; Nobuo Kanazawa; Liliya Zisova; Ana-Maria Forsea; Christos C Zouboulis
Journal:  Wien Med Wochenschr       Date:  2013-01-15

2.  Kba.62 and S100 protein expression in cytologic samples of metastatic malignant melanoma.

Authors:  Gulsun Erdag; Sinchita Roy Chowdhuri; Patricia Fetsch; Dana Erickson; Marybeth S Hughes; Armando C Filie
Journal:  Diagn Cytopathol       Date:  2013-04-03       Impact factor: 1.582

Review 3.  Solitary, multiple, benign, atypical, or malignant: the "Granular Cell Tumor" puzzle.

Authors:  Isidro Machado; Julia Cruz; Javier Lavernia; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2015-12-05       Impact factor: 4.064

Review 4.  Investigation of cAMP microdomains as a path to novel cancer diagnostics.

Authors:  Garrett Desman; Caren Waintraub; Jonathan H Zippin
Journal:  Biochim Biophys Acta       Date:  2014-09-07

5.  Canine and feline uveal melanocytic tumours: Histologic and immunohistochemical characteristics of 32 cases.

Authors:  Matheus Vilardo Lóes Moreira; Ingeborg Maria Langohr; Marina Rios de Araújo Campos; Enio Ferreira; Bárbara Carvalho; Guilherme Reis Blume; Fabiano Montiani-Ferreira; Roselene Ecco
Journal:  Vet Med Sci       Date:  2022-02-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.